SC
CGON icon

Steven Cohen’s CG Oncology CGON Stock Holding History

Steven Cohen’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-399,392
Closed -$26.1M – 4072
2026
Q1 		$27M Buy
399,392
+248,029
+164% +$14.1M 0.03% 660
2025
Q4 		$6.28M Sell
151,363
-1,372,046
-90% -$56.8M 0.01% 1671
2025
Q3 		$61.4M Buy
1,523,409
+48,116
+3% +$1.4M 0.1% 222
2025
Q2 		$38.4M Sell
1,475,293
-191,881
-12% -$4.62M 0.08% 305
2025
Q1 		$40.8M Buy
1,667,174
+1,358,915
+441% +$38.2M 0.09% 254
2024
Q4 		$8.84M Sell
308,259
-437,804
-59% -$15M 0.02% 736
2024
Q3 		$28.1M Buy
746,063
+635,653
+576% +$22.3M 0.07% 321
2024
Q2 		$3.49M Sell
110,410
-75,827
-41% -$2.63M 0.01% 944
2024
Q1 		$8.18M Buy
+186,237
New +$7.61M 0.02% 789

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's CGON Position: Q2 2026 in Review

Steven Cohen sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 399,392 shares — an estimated $26.1M sold.

Steven Cohen first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $61.4M in Q3 2025. 226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Steven Cohen reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 399,392 CG Oncology shares in Q2 2026, an estimated $26.1M.
  • Steven Cohen first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
  • Steven Cohen's CG Oncology position peaked at $61.4M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.